Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: A critical review of comparative studies

European Journal of Cancer Part A

Volumn 32, Issue SUPPL. 5, 1996, Pages

  Labianca, R ^a   Pessi, A ^a   Facendola, G ^a   Pirovano, M ^a   Luporini, G ^a  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

5 fluorouracil; colorectal cancer; leucovorin; treatment schedules

Indexed keywords

DIPYRIDAMOLE; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; INTERFERON; IRINOTECAN; METHOTREXATE; OXALIPLATIN; RALTITREXED;

ADVANCED CANCER; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL;

EID: 0029989892     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00330-9     Document Type: Conference Paper

References (55)

1. Moertel CG. Chemotherapy for colorectal cancer. New Engl J Med 1994, 330, 1136-1142.
2. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion 5-fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. A MAOP study. J Clin Oncol 1989, 7, 425-432.
3. Anderson N, Lokich JJ. Controversial issues in 5-fluorouracil infusion use. Cancer 1992, 70, 998-1002.
4. Machover D, Schwarzenberg L, Goldschmidt E, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep 1982, 66, 1803-1807.
5. Madajewicz P. Phase I/II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res 1984, 44, 4667-4669.
6. Brenckman WD, Laufman LR, Adamiewicz BB, et al. Is fluorouracil as effective as equitoxic doses of 5FU plus high dose oral leucovorin in colorectal carcinoma? Proceedings ASCO 1990, 9, 421 (Abstract).
7. Luporini G, Labianca R, Pancera G. Treatment of metastatic colorectal cancer: improvement of 5-fluorouracil activity with modulating agents. Forum 1991, 1, 246-256.
8. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and leucovorin in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987, 5, 1559-1565.
9. Petrelli N, Douglass HD, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma. A perspective randomized phase III trial. J Clin Oncol 1989, 7, 1419-1426.
10. Nobile MT, Vidili MG, Sobrero A, et al. 5-fluorouracil alone or combined with high-dose folinic acid in advanced colorectal cancer patients: a randomized trial. Proceedings ASCO 1988, 7, 97 (Abstract).
11. Valone FH, Friedman MA, Wittlinger PS, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil or sequential methotrexate, fluorouracil, leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989, 7, 1427-1436.
12. Di Costanzo F, Bartolucci R, Sofra M, et al. 5-fluorouracil alone versus high dose folinic acid and 5FU in advanced colorectal cancer. A randomized trial of the Italian Oncology Group for Clinical Research. Proceedings ASCO 1989, 8, 410 (Abstract).
13. Labianca R, Pancera G, Aitini E, et al. Folinic acid + 5-fluorouracil (5FU) versus equidose 5FU in advanced colorectal cancer. Phase III study of GISCAD (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 1991, 2, 673-679.
14. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil. Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 7, 1407-1417.
15. Doroshow JH, Multhauf P, Leong L, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990, 8, 491-501.
16. Erlichman C, Fine S, Wong A, et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988, 6, 469-475.
17. Cricca A, Martoni A, Guaraldi M, et al. Randomized clinical trial of 5FU + folinic acid versus 5FU in advanced gastrointestinal cancers. Proceedings ESMO 1988, 13, 427 (Abstract).
18. O'Connell MJ, Maillard J, MacDonald J, et al. An intergroup trial of intensive course 5FU and low-dose leucovorin as surgical adjuvant therapy for high risk colon cancer. Proceedings ASCO 1993, 12, 552 (Abstract).
19. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as post operative adjuvant therapy for primary colon cancer: results from the National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993, 11, 1879-1887.
20. Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994, 106, 899-906.
21. IMPACT investigators (Labianca R, Marsoni S, Pancera G, et al.). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345, 939-944.
22. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896-903.
23. Jaeger E, Klein O, Bernhard H, et al. Weekly high-dose folinic acid (FA)/5-fluorouracil (FU) versus low-dose FA/FU in advanced colorectal cancer. Results of randomized multicenter trial. Proceedings ASCO 1994, 13, 556 (Abstract).
24. Poon MA, O'Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991, 9, 1967-1972.
25. Valsecchi R, Labianca R, Cascinu S, et al. High-dose versus low-dose L-leucovorin as a modulator of 5 days' 5-fluorouracil in advanced colorectal cancer: a GISCAD phase III study. Proceedings ASCO 1995, 14, 457 (Abstract).
26. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994, 12, 14-20.
27. de Gramont A, Bosset JF, Milan C, et al. A prospective randomized trial comparing 5FU bolus with low-dose folinic acid (FUFOL1d) and 5FU bolus plus continuous infusion with high-dose folinic acid (LV5FU2) for advanced colorectal cancer. Proceedings ASCO 1995, 14, 455 (Abstract).
28. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995, 13, 1303-1311.
29. Borner MM, Sartor O. More is not always better: a case for low-dose leucovorin. J Clin Oncol 1993, 11, 382-383.
30. Petrelli N, Rustum Y. Fluorouracil and leucovorin: there is a choice. J Clin Oncol 1993, 11, 1434.
31. Brook J. Fluorouracil and low-dose leucovorin versus fluorouracil and high-dose leucovorin. What is the real cost? What is the answer? J Clin Oncol 1995, 13, 1830-1831.
32. Cunningham D, Zalcberg J, Rath U, et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. Eur J Cancer 1995, 31A, (12), 1945-1954.
33. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Superiority of sequential methotrexate, fluorouracil and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. J Clin Oncol 1989, 7, 1437-1446.
34. Advanced Colorectal Cancer Meta-analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994, 12, 960-969.
35. Blijham GH, Stellestags J, Sahmoud T, et al. The modulation of high-dose 5-fluorouracil with low-dose methotrexate in metastatic colorectal cancer. A phase III study of the EORTC GI Cancer Cooperative Group. Proc Am Soc Clin Oncol 1993, 12, 586 (Abstract).
36. Herrmann R, Knuth A, Kleeberg U, et al. Sequential methotrexate and 5-fluorouracil (FU) vs FU alone in metastatic colorectal cancer. Ann Oncol 1992, 3, 539-543.
37. Machiavelli M, Leone BA, Romero A, et al. Advanced colorectal carcinoma: a prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone. Am J Clin Oncol 1991, 14, 211-217.
38. Delfino C, Caccia G, Maniago O. 5-fluorouracil alone versus methotrexate + leucovorin + FU in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1992, 11, 521 (Abstract).
39. Abad A, Garcia P, Gravalos C, et al. Phase III trial with methotrexate, 5-FU and high-dose leucovorin vs. 5-FU, leucovorin vs. 5-FU in advanced and metastatic colorectal cancer. Proc Am Soc Clin Oncol 1992, 11, 459 (Abstract).
40. Marsh J, Bertino J, Katz KH, et al. The influence of drug interval on the effect of methotrexate and 5-fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 1991, 9, 371-380.
41. Elias L. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interaction with halogenated pyrimidine antimetabolites. Cancer Res 1988, 48, 4868-4873.
42. Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant alpha-2a interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989, 7, 1769-1775.
43. Wadler S, Wiernik PM. Clinical update on the role of fluorouracil and recurrent interferon alpha-2a in the treatment of colorectal cancer. Semin Oncol 1990, 18 (suppl), 16-23.
44. Kemeny N, Younes A, Seiter K, et al. Interferon alpha-2a and 5-flurouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer 1990, 66, 2470-2475.
45. Pazdur R, Ajani JA, Patt YZ. Phase II study of fluorouracil and recombinant interferon alpha-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990, 8, 2027-2031.
46. Labianca R, Giaccon G, Barni S, et al. Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon alpha-2b and folinic acid. The GISCAD experience. Eur J Cancer 1994, 30A, 1611-1616.
47. York M, Greco FA, Figlin RA, et al. A randomized phase III trial comparing 5FU with or without interferon alpha-2a for advanced colorectal cancer. Proceedings ASCO 1993, 12, 590 (Abstract).
48. Hill M, Norman A, Cunningham D, et al. Royal Marsden phase III trial of fluorouracil with or without interferon alpha-2b in advanced colorectal cancer. J Clin Oncol 1995, 13, 1297-1302.
49. Kocha W. 5-fluorouracil plus interferon alpha-2a (Roferon-A) versus 5-fluorouracil plus leucovorin in metastatic colorectal cancer. Results of a multicentre, multinational phase III study. Proceedings ASCO 1993, 12, 562 (Abstract).
50. Kohne CH, Wilke H, Hecker H, et al. Interferon alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. Ann Oncol 1995, 6, 461-466.
51. O'Dwyer PJ, Paul AR, Walczac J, et al. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 1990, 8, 1497-1503.
52. Kohne CH, Hiddemann W, Schuller J, et al. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. J Clin Oncol 1995, 13, 1201-1208.
53. Aschele C, Sobrero A, Faderan MA, et al. Novel mechanism of resistance to 5-fluorouracil in human colon cancer (HCT-8) sub-lines following exposure to two different clinically relevant dose schedules. Cancer Res 1992, 52, 1855-1864.
54. Mori A, Bertoglio S, Guglielmi A, et al. Activity of continuous infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 1993, 33, 179-180.
55. Sobrero A, Aschele C, Guglielmi A, et al. Schedule selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer. Clin Cancer Res 1995, 1, 955-960.